natgillin/translations-raw huggingface dataset:
Stop taking Ebymect and see a doctor as soon as possible if you notice any of the following serious or potentially serious effects: 
Nehajte jemati zdravilo Ebymect in čim prej obiščite zdravnika, če opazite katerega od naslednjih resnih ali potencialno resnih neželenih učinkov:
Ebymect should not be used to treat this condition. 
Za zdravljenje te bolezni se zdravila Ebymect ne sme uporabljati.
The primary assessment of safety and tolerability was conducted in a pre-specified pooled analysis of 13 short-term (up to 24 weeks) placebo-controlled studies with 2,360 subjects treated with dapagliflozin 10 mg and 2,295 treated with placebo. 
Primarno oceno varnosti in prenašanja so izvedli v vnaprej opredeljeni kumulativni analizi 13 kratkotrajnih (do 24 tednov trajajočih) s placebom kontroliranih študij v katere je bilo vključenih 2.360 preiskovancev, zdravljenih z 10 mg dapagliflozina, in 2.295 preiskovancev, ki so prejemali placebo.
Stop taking Ebymect and see a doctor straight away if you notice any of the following serious or potentially serious side effects: 
Nehajte jemati zdravilo Ebymect in takoj obiščite zdravnika, če opazite katerega od naslednjih resnih ali potencialno resnih neželenih učinkov:
Vulvovaginitis , balanitis and related genital infections 
Infekcijske in parazitske bolezni vulvovaginitis, balanitis in sorodne okužbe spolovil
If you forget to take Ebymect 
Če ste pozabili vzeti zdravilo Ebymect
Patients insufficiently controlled on metformin alone or in combination with other medicinal products for the treatment of diabetes should receive a total daily dose of Ebymect equivalent to dapagliflozin 10 mg, plus the total daily dose of metformin, or the nearest therapeutically appropriate dose, already being taken. 
Bolniki, ki niso zadostno urejeni s samim metforminom ali metforminom v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni morajo dobiti celokupni dnevni odmerek zdravila Ebymect, ki ustreza odmerku dapagliflozina 10 mg in celokupnemu dnevnemu odmerku metformina oziroma že uporabljanemu njegovemu najbližjemu terapevtsko ustreznemu odmerku.
Ebymect is used for a type of diabetes called “type 2 diabetes” in adult patients (aged 18 years and older) and usually occurs when you are older. 
Zdravilo Ebymect se uporablja za zdravljenje sladkorne bolezni, ki jo imenujemo "sladkorna bolezen tipa 2", pri odraslih bolnikih (starih 18 let in več).
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say it is essentially ‘sodium-free'. 
Zdravilo Ebymect vsebuje manj kot 1 mmol natrija (23 mg) na odmerek, kar v bistvu pomeni ‘brez natrija'.
Ebymect combines two anti-hyperglycaemic medicinal products with different and complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: dapagliflozin, a SGLT2 inhibitor, and metformin hydrochloride, a member of the biguanide class. 
Zdravilo Ebymect je kombinacija dveh antihiperglikemičnih učinkovin z različnima in komplementarnima mehanizmoma delovanja, ki izboljšata urejenost glikemije pri bolnikih s sladkorno boleznijo tipa 2: dapagliflozina, zaviralca SGLT2, in metforminijevega klorida, ki spada v skupino bigvanidov.
After administration of a 50 mg C]-dapagliflozin dose, 96% was recovered, 75% in urine and 21% in faeces. 
C]-dapagliflozina se je izločenega pojavilo 96 %, in sicer 75 % v urinu in 21 % v blatu.
Mean eGFR was 85.2 mL/min/1.73 m of patients had eGFR < 60 mL/min/1.73 m2, and 30.3% of patients had micro- or macroalbuminuria (urine albumin to creatinine ratio [UACR] ≥ 30 to ≤ 300 mg/g or > 300 mg/g, respectively). 
Povprečna eGFR je bila 85,2 ml/min/1,73 m2, 7,4 % bolnikov je imelo eGFR < 60 ml/min/1,73 m2 in 30,3 % bolnikov je imelo mikro- ali makroalbuminurijo (razmerje med albuminom in kreatininom v urinu [UACR] ≥ 30 do ≤ 300 mg/g [mikro oz. > 300 mg/g [makro ).
The coadministration of dapagliflozin and metformin has been studied in subjects, with type 2 diabetes, inadequately controlled on diet and exercise alone, and in subjects inadequately controlled on metformin alone or in combination with a DPP-4 inhibitor (sitagliptin), sulphonylurea or insulin. 
Sočasno uporabo dapagliflozina in metformina so raziskali pri preiskovancih s sladkorno boleznijo tipa 2, neustrezno urejenih samo z dieto in telesno dejavnostjo in pri preiskovancih, ki niso bili zadostno urejeni z metforminom samim ali v kombinaciji z zaviralcem DPP-4 (sitagliptin), sulfonilsečnino ali insulinom.
Renal composite endpoint defined as: sustained confirmed ≥ 40% decrease in eGFR to eGFR <60 mL/min/1.73 m 2 and/or end stage renal disease (dialysis ≥ 90 days or kidney transplantation, sustained confirmed eGFR < 15 mL/min/1.73 m 2) and/or renal or cardiovascular death. 
Ledvični sestavljeni opazovani dogodek je bil opredeljen kot: trajno, potrjeno ≥ 40-odstotno zmanjšanje eGFR do eGFR < 60 ml/min/1,73 m2 in/ali končna odpoved ledvic (dializa ≥ 90 dni ali presaditev ledvice, trajno, potrjeno zmanjšanje eGFR na < 15 ml/min/1,73 m2) in/ali ledvična ali srčno-žilna smrt.
film-coating: polyvinyl alcohol (E1203), macrogol 3350 (E1521), talc (E553b), titanium dioxide (E171), iron oxide yellow (E172), iron oxide red (E172) (only Ebymect 5 mg/850 mg). 
filmska obloga: polivinilalkohol (E1203), makrogol 3350 (E1521), smukec (E553b), titanov dioksid (E171), rumeni železov oksid (E172), rdeči železov oksid (E172) (samo zdravilo Ebymect 5 mg/850 mg).
• diarrhoea or stomach ache • loss of appetite 
• driska ali bolečine v trebuhu
In active- and placebocontrolled clinical trials (dapagliflozin, N=5936, All control, N=3403), the frequency of rash was similar for dapagliflozin (1.4%) and all control (1.4%), respectively. 
5936, vse kontrolne osebe; n = 3403) je bila pogostnost izpuščaja z dapagliflozinom (1,4 %) podobna kot pri vseh kontrolnih osebah (1,4 %).
Hydroxypropyl cellulose (E463) Microcrystalline cellulose (E460(i)) Magnesium stearate (E470b) Sodium starch glycolate type A 
Jedro tablete hidroksipropilceluloza (E463) mikrokristalna celuloza (E460(i)) magnezijev stearat (E470b) natrijev karboksimetilškrob, vrsta A
Abbreviations: QD: once daily; BID: twice daily Metformin ≥ 1500 mg/day; Sitagliptin 100 mg/day LOCF: Last observation (prior to rescue for rescued subjects) carried forward Placebo-controlled 16-week study All randomised subjects who took at least one dose of double-blind study medicinal product during the short-term double-blind period Least squares mean adjusted for baseline value p-value < 0.0001 versus placebo + oral glucose-lowering medicinal product p-value < 0.05 versus placebo + oral glucose-lowering medicinal product The percent change in body weight was analysed as a key secondary endpoint (p < 0.0001); absolute body weight change (in kg) was analysed with a nominal p-value (p < 0.0001). 
Metformin ≥ 1500 mg/dan Sitagliptin 100 mg/dan LOCF: prenos zadnjega opažanja (pred rešilnim zdravljenjem za rešene preiskovance) [Last observation carried forward] S placebom kontrolirana 16-tedenska študija Vsi randomizirani preiskovanci, ki so prejeli vsaj en odmerek dvojno slepljenega raziskovanega zdravila med kratkoročnim dvojno slepim obdobjem Povprečje najmanjših kvadratov, korigirano za izhodiščno vrednost Vrednost p < 0,0001 v primerjavi s kombinacijo placebo + peroralni antidiabetik Vrednost p < 0,05 v primerjavi s kombinacijo placebo + peroralni antidiabetik Odstotek spremembe telesne mase so analizirali kot sekundarni opazovani dogodek (p < 0,0001); absolutno spremembo telesne mase (v kg) so analizirali z nominalno vrednostjo p (p < 0,0001).
In the placebo group there was an increase of 10.5 IU/day and 18.3 IU/day from baseline (mean average dose of 84 and 92 IU/day) at Weeks 48 and 
V skupini s placebom so 48. teden ugotovili povečanje za 10,5 i.e./dan (povprečni odmerek 84 i.e./dan) in 104. teden povečanje za 18,3 i.e./dan (povprečni odmerek 92 i.e./dan) v primerjavi z izhodiščem.
• Diabetic ketoacidosis, seen rarely (may affect up to 1 in 1,000 people) These are the signs of diabetic ketoacidosis (see also section 2 Warnings and precautions): - increased levels of “ketone bodies” in your urine or blood - rapid weight loss - feeling sick or being sick - stomach pain - excessive thirst - fast and deep breathing - confusion - unusual sleepiness or tiredness - a sweet smell to your breath, a sweet or metallic taste in your mouth or a different odour to your urine or sweat. 
• Diabetična ketoacidoza, ki je redka (pojavi se lahko pri največ 1 od 1.000 bolnikov) Znaki diabetične ketoacidoze (glejte tudi 2. poglavje, Opozorila in previdnostni ukrepi) so: - zvišana raven "ketonskih teles" v urinu ali krvi - hitra izguba telesne mase - slabost ali bruhanje
Talk to your doctor, pharmacist or nurse before taking Ebymect, and during treatment: 
Pred začetkom jemanja zdravila Ebymect in med zdravljenjem se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro:
The following adverse reactions have been identified in the placebo-controlled dapagliflozin plus metformin clinical studies, dapagliflozin clinical studies and metformin clinical studies and postmarketing experience. 
V s placebom kontroliranih kliničnih študijah kombinacije dapagliflozina in metformina, kliničnih študijah dapagliflozina, kliničnih študijah metformina in med obdobjem po odobritvi dovoljenja za promet so ugotovili naslednje neželene učinke.
Ebymect should not be initiated in patients with GFR < 60 mL/min and should be discontinued at GFR persistently below 45 mL/min (see section 4.2). 
Zdravljenje je treba prekiniti pri GFR trajno pod 45 ml/min (glejte poglavje 4.2).
Hypoglycaemia (when used with SU or insulin) 
Presnovne in prehranske motnje hipoglikemija (med uporabo s sulfonilsečnin ami ali insulinom)
a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patient-years (p=0.021); a significant reduction in the absolute risk of myocardial infarction: metformin 11 events/1,000 patient-years, diet alone 18 events/1,000 patient-years, (p=0.01). 
• značilno zmanjšanje absolutnega tveganja za celotno umrljivost: metformin 13,5 dogodka/1000 bolnik-let v primerjavi s samo dieto 20,6 dogodka/1000 bolnik-let (p = 0,011) in v primerjavi z združenimi podatki skupin monoterapije s sulfonilsečnino in z insulinom 18,9 dogodka/1000 bolnik-let, (p = 0,021);
You may need more frequent blood glucose and kidney function tests, or your doctor may adjust the dosage of Ebymect. 
Morda boste morali pogosteje opravljati preiskave glukoze v krvi in delovanja ledvic,
on one side and “1069” on the other side. 
Na eni strani imajo vtisnjeno oznako "5/1000" in na drugi strani "1069".
Dapagliflozin as an add-on with either metformin alone, metformin in combination with sitagliptin, sulphonylurea or insulin (with or without additional oral glucose-lowering medicinal products, including metformin) resulted in statistically significant mean reductions in HbA1c at 24 weeks compared with subjects receiving placebo (p < 0.0001; Tables 4, 5 and 6). 
Dapagliflozin kot dodatek bodisi metforminu samemu, metforminu v kombinaciji s sitagliptinom, sulfonilsečnino ali insulinom (z dodatnimi peroralnimi antidiabetiki (vključno z metforminom) ali brez njih) je po 24 tednih statistično značilno znižal HbA1c v primerjavi s prejemniki placeba (p < 0.0001, preglednice 4, 5 in 6).
Rare cases of diabetic ketoacidosis (DKA), including life-threatening and fatal cases, have been reported in patients treated with sodium-glucose co-transporter 2 (SGLT2) inhibitors, including dapagliflozin. 
Pri bolnikih, zdravljenih z zaviralci natrij-glukoznega soprenašalca 2 (SGLT2 - sodium-glucose cotransporter 2), (vključno z dapagliflozinom), so poročali o redkih primerih diabetične ketoacidoze (DKA), med njimi tudi o smrtno nevarnih in smrtnih primerih.
In a dedicated study in diabetic patients with an eGFR ≥ 45 to < 60 mL/min/1.73 m2, treatment with dapagliflozin demonstrated reductions in FPG at Week 24: -1.19 mmol/L (-21.46 mg/dL) compared to0.27 mmol/L (-4.87 mg/dL) for placebo (p=0.001). 
V namenski študiji pri sladkornih bolnikih z eGFR od ≥ 45 do < 60 ml/min/1,73 m2 je zdravljenje z dapagliflozinom 24. teden doseglo znižanje glukoze v plazmi na tešče: sprememba je znašala -1,19 mmol/l (-21,46 mg/dl) v primerjavi z -0,27 mmol/l (-4,87 mg/dl) s placebom (p = 0,001).
• Ebymect 5 mg/850 mg are 9.5 x 20 mm oval, brown film-coated tablets. 
• Zdravilo Ebymect 5 mg/850 mg so 9,5 x 20 mm velike, ovalne, rjave filmsko obložene tablete.
Subjects (%) achieving HbA1c 7% 
Preiskovanci (%), ki so dosegli: HbA1c < 7 % Korigirano za izhodišče
Factors that may increase the risk of lactic acidosis (see section 4.4) should be reviewed before considering initiation of metformin in patients with GFR < 60 mL/min. 
Pri bolnikih z GFR < 60 ml/min je treba pred uvedbo zdravila Ebymect pregledati dejavnike, ki lahko povečajo tveganje za laktacidozo (glejte poglavje 4.4).
Each Ebymect 5 mg/850 mg film-coated tablet (tablet) contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin and 850 mg metformin hydrochloride. 
Ena filmsko obložena tableta (tableta) zdravila Ebymect 5 mg/850 mg vsebuje dapagliflozin-propandiol monohidrat v količini, ki ustreza 5 mg dapagliflozina, in 850 mg metforminijevega klorida.
Analysis of the results for overweight patients treated with metformin after failure of diet alone showed: a significant reduction of the absolute risk of any diabetes-related complication in the metformin group (29.8 events/1,000 patient-years) versus diet alone (43.3 events/1,000 patient-years), p=0.0023, and versus the combined sulphonylurea and insulin monotherapy groups (40.1 events/1,000 patient-years), p=0.0034; a significant reduction of the absolute risk of any diabetes-related mortality: metformin 7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017; 
• značilno zmanjšanje absolutnega tveganja vseh zapletov sladkorne bolezni v skupini z metforminom (29,8 dogodka/1000 bolnik-let) v primerjavi z dieto samo (43,3 dogodka/1000 bolnik-let), p = 0,0023, ter v primerjavi z združenimi podatki skupin monoterapije s sulfonilsečnino in z insulinom (40,1 dogodka/1000 bolnik-let), p = 0,0034;
Each Ebymect 5 mg/1,000 mg film-coated tablet (tablet) contains dapagliflozin propanediol monohydrate equivalent to 5 mg dapagliflozin and 1,000 mg metformin hydrochloride. 
Ena filmsko obložena tableta (tableta) zdravila Ebymect 5 mg/1000 mg vsebuje dapagliflozin-propandiol monohidrat v količini, ki ustreza 5 mg dapagliflozina, in 1000 mg metforminijevega klorida.
Ebymect 5 mg/850 mg film-coated tablets Polyvinyl alcohol (E1203) Macrogol 3350 (E1521) Talc (E553b) 
Ebymect 5 mg/1000 mg filmsko obložene tablete polivinilalkohol (E1203) makrogol 3350 (E1521) smukec (E553b) titanov dioksid (E171) rumeni železov oksid (E172)
Liver function disorders Hepatitis 
Bolezni jeter, žolčnika in motnje delovanja jeter
104, respectively. 
z -0,7 %.
Metformin may act via three mechanisms: by reduction of hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis; by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation in muscle; by delaying intestinal glucose absorption. 
• z zmernim povečanjem občutljivosti za insulin, s čimer izboljša periferni privzem glukoze in porabo v mišicah,
Change from baseline Difference from placebo d 
Izhodišče (povprečje) Sprememba od izhodišča Razlika v primerjavi s placebom d
What you need to know before you take Ebymect 3. 
Kaj je zdravilo Ebymect in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Ebymect Kako jemati zdravilo Ebymect Možni neželeni učinki
Powder and solvent for concentrate for solution for infusion 
Prašek in vehikel za koncentrat za raztopino za infundiranje
concentrate: 25 ml (20 mg/ml); diluent: 500 ml 
25 ml (20 mg/ml) vehikel: 500 ml
Intravenous use powder: vial (glass); bottle (glass) 
Prašek: viala (steklo); vehikel: steklenica (steklo)
10 vials + 3 bottles 
10 vial steklenice
Pack size 
Koncentrat:
7 (7 x 1) vials + 7 (7 x 1) pre-filled solvent syringes + 7 (7 x 1) vial adapters + 7 (7 x 1) needles + 14 (7 x 2) swabs (multipack) 
7 (7 x 1) vial + 7 (7 x 1) napolnjenih injekcijskih brizg z vehiklom + 7 (7 x 1) nastavkov za vialo + 7 (7 x 1) igel + 14 (7 x 2) blazinic (večodmerno pakiranje)
7 (7 kits x (1 vial + 1 pre-filled solvent syringe + 1 vial adapter + 1 needle + 2 swabs)) (multipack) 
7 (7 kompletov x (1 viala + 1 napolnjena injekcijska brizga + 1 nastavek za vialo + 1 igla + 2 blazinici)) (večodmerno pakiranje)
1 vial + 1 pre-filled solvent syringe + 1 vial adapter + 1 needle + 2 swabs 
1 napolnjena injekcijska brizga z vehiklom + 1 nastavek za vialo + 1 igla + 2 blazinici
Pharmaceutical Form Route of administration 
Farmacevtska oblika Pot uporabe Pakiranje
Blister (PVC/alu) 60 
filmsko obložene tablete peroralna uporabaplastenka (HDPE) 60
Tradename Strength 
Ime zdravila Jakost
Dr Harald Enzmann (Germany) 
Dr. Harald Enzmann (Nemčija)
The European Commission issued a decision on 2 June 2010. 
Evropska komisija je odločitev izdala dne 4. junija 2010.
Prof Pieter de Graeff (the Netherlands) 
Prof. Pieter de Graeff (Nizozemska)
As, the Member States were not able to reach an agreement, the German medicines regulatory agency referred the matter to the CHMP for arbitration on 29 October 2009. 
Ker države članice niso dosegle soglasja, je nemški regulatorni organ za zdravila dne 29. oktobra 2009 zadevo napotili na CHMP v arbitražo.
The grounds for the referral were concerns from Sweden that patients would be exposed to the antioxidant butylated hydroxyanisole (BHA) unnecessarily. 
Razlogi za napotitev so bili pomisleki Švedske, da bi bili bolniki po nepotrebnem izpostavljeni antioksidantu butiliran hidroksianizol (BHA).
Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of Clopidogrel Teva outweigh its risks and recommended that the marketing authorisation be granted in all the concerned Member States. 
Na podlagi ocenjevanja trenutno razpoložljivih podatkov in znanstvene razprave v okviru odbora je CHMP zaključil, da koristi zdravila Clopidogrel Teva odtehtajo njegova tveganja, zato je priporočil odobritev dovoljenja za promet z zdravilom v vseh zadevnih državah članicah.
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Clopidogrel Teva outweigh its risks, and the marketing authorisation can be granted in Germany and in the following Member States of the EU: Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Romania, Slovakia, Spain, Sweden and the United Kingdom. 
Odbor za zdravila za uporabo v humani medicini (CHMP) pri Agenciji je zaključil, da koristi zdravila Clopidogrel Teva odtehtajo njegova tveganja in da se lahko dovoljenje za promet z zdravilom odobri v Nemčiji in tudi v naslednjih državah članicah EU: v Avstriji, Belgiji, Bolgariji, na Cipru, Češkem, Danskem, v Estoniji, na Finskem, v Franciji, Grčiji, na Madžarskem, Irskem, v Italiji, Latviji, Litvi, Luksemburgu, na Nizozemskem, Norveškem, Poljskem, v Romuniji, na Slovaškem, v Španiji, na Švedskem in v Združenem kraljestvu.
The European Medicines Agency has completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Clopidogrel Teva and associated names. 
Evropska agencija za zdravila je zaključila arbitražni postopek, do katerega je prišlo po nesoglasju med državami članicami Evropske unije (EU) glede odobritve zdravila Clopidogrel Teva in povezanih imen/povezana imena.
This means that it helps to prevent blood clots from forming. 
To pomeni, da pomaga pri preprečevanju tvorbe krvnih strdkov.
It is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) such as a heart attack or stroke. 
Uporablja se pri odraslih za preprečevanje aterotrombotičnih dogodkov (težav, ki jih povzročajo krvni strdki in otrdelost arterij), kot je srčni napad ali infarkt.
Why was Clopidogrel Teva reviewed? 
Zakaj je bilo zdravilo Clopidogrel Teva pregledano?
This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke. 
To preprečuje, da bi trombociti postali „lepljivi“, kar zmanjšuje tveganje za nastanek krvnega strdka in prispeva k preprečevanju novega srčnega napada ali kapi.
in other Member States (the ‘concerned Member States', in this instance Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Poland, Romania, Slovakia, Spain, Sweden and the United Kingdom). 
To je postopek, pri katerem ena država članica („referenčna država članica“, v tem primeru Nemčija), oceni zdravilo z namenom odobritve dovoljenja za promet z njim, ki bo veljavno v tej državi in v drugih državah članicah („zadevnih državah članicah“, v tem primeru v Avstriji, Belgiji, Bolgariji, na Cipru, Češkem, Danskem, v Estoniji, na Finskem, v Franciji, Grčiji, na Madžarskem, Irskem, v Italiji, Latviji, Litvi, Luksemburgu, na Nizozemskem, Norveškem, Poljskem, v Romuniji, na Slovaškem, v Španiji, na Švedskem in v Združenem kraljestvu).
Clopidogrel Teva is a generic medicine based on a ‘reference medicine', Plavix which is authorised in the EU. 
Clopidogrel Teva je generično zdravilo na osnovi „referenčnega zdravila“ Plavix, ki je odobreno v EU.
Clopidogrel base is less stable than the salt form, and BHA is included in the medicine to stabilise it. 
Klopidogrelna baza je manj stabilna kot sol, zato je za njeno stabilizacijo v zdravilo vključen BHA.
The company had chosen to use ‘clopidogrel base' as the form of the active substance in the medicine, and not a salt such as the ‘hydrogen sulfate salt' used in Plavix. 
Družba se je odločila, da kot obliko zdravilne učinkovine v zdravilu uporabi „klopidogrelno bazo“ in ne sol, kot npr. „hidrogensulfatna sol“, ki se uporablja v zdravilu Plavix.
What is Clopidogrel Teva? 
Kaj je zdravilo Clopidogrel Teva?
Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface. 
Klopidogrel ustavi agregacijo trombocitov tako, da spojini, imenovani adenozin difosfat (ADP), prepreči vezavo na posebne receptorje na njihovi površini.
When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together). 
Kri se strjuje zaradi posebnih celic v krvi, imenovanih trombociti, ki se agregirajo (zlepljajo) med seboj.
Teva Pharma B.V. submitted Clopidogrel Teva to Germany for a decentralised procedure. 
je predložila zdravilo Clopidogrel Teva Nemčiji v decentraliziran postopek.
Clopidogrel Teva is a medicine that contains the active substance clopidogrel. 
Clopidogrel Teva je zdravilo, ki vsebuje zdravilno učinkovino klopidogrel.
4 June 2010 
4. junij 2010
18 February 2010 
18. februar 2010
18 January 2010 
18. januar 2010
The active substance, clopidogrel, is an inhibitor of platelet aggregation. 
Zdravilna učinkovina klopidogrel je zaviralec agregacije trombocitov.
• There is insufficient data on Abseamed to know the size of any increased immunogenicity risk with sc use 
• Podatkov o zdravilu Abseamed je premalo, da bi vedeli, za koliko se poveča tveganje za pojav imunogenosti pri subkutani uporabi zdravila.
On 11 March 2016, pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested the opinion of the Agency on whether the marketing authorisation of Zydelig (idelalisib) should be maintained, varied, suspended or revoked. 
Dne 11. marca 2016, v skladu s členom 20 Uredbe (ES) št. 726/2004, je Evropska komisija agencijo zaprosila za mnenje o tem, ali je treba ohraniti, spremeniti, začasno odvzeti ali preklicati dovoljenje za promet z zdravilom Zydelig (idelalizib).